These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2208182)

  • 1. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 5. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.
    Lang AE; Riley DE; Vachon L; Lataste X
    Can J Neurol Sci; 1990 Nov; 17(4):416-9. PubMed ID: 2276100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
    Metman LV; Sethy VH; Roberts JR; Bravi D; Hoff JI; Mouradian MM; Chase TN
    Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.